Thrombophilia testing looks for inherited or acquired conditions associated with blood clots. Common inherited tests include factor V Leiden, the prothrombin G20210A variant, and deficiencies of antithrombin, protein C, or protein S. A typical panel may also include lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies used in evaluating antiphospholipid syndrome.
Finding a trait can explain part of a person's susceptibility. Explanation, however, is not the same as better management. A useful test changes a decision whose benefits and harms matter. If anticoagulation duration, prevention during a future risk period, pregnancy planning, or family counseling will be the same regardless of the result, testing can add cost, uncertain labels, repeat work, and anxiety without improving outcomes.
The 2023 American Society of Hematology guideline is more nuanced than "never test" or "test every unexplained clot." It recommends or suggests testing only in selected scenarios and advises against it in many common ones. Nearly all recommendations rely on very low-certainty evidence, so your decision has to stay tied to the exact scenario.
What a panel is trying to answer#
Venous thromboembolism includes deep-vein thrombosis and pulmonary embolism. The immediate priorities are confirming the clot, assessing severity, identifying a major provoking factor, and starting appropriate treatment. Thrombophilia testing rarely changes emergency management.
Later questions include how long anticoagulation should continue, whether a particular future situation needs prevention, and whether relatives need targeted counseling. The chance of recurrence after the index clot and the risk of bleeding on continued anticoagulation usually drive the duration decision. A test helps only when its result can move that balance across a treatment threshold.
Panels combine conditions with very different prevalence and implications. Heterozygous factor V Leiden is more common and generally has a different risk profile from antithrombin deficiency. Antiphospholipid syndrome is not an inherited mutation. Treating every positive item as equivalent is a major interpretive error.
Why the trigger often matters more than the trait#
A clot following major surgery has a clear, strong, temporary trigger. Once recovery is complete, recurrence risk is usually lower than after an unprovoked event. ASH recommends not testing for thrombophilia to guide treatment duration after surgery-provoked venous thromboembolism, and a positive inherited result often would not justify changing a time-limited plan, while a negative result would not erase the fact that a clot occurred.
The category "provoked" is not uniform. Nonsurgical transient factors can include pregnancy, the postpartum period, or estrogen-containing contraception. They can include prolonged illness or other circumstances. ASH conditionally suggests testing after some nonsurgical transient-risk or hormone-associated events if the local standard would otherwise stop anticoagulation after initial treatment and a positive result would lead to extended treatment.
That suggestion should not be converted into automatic testing. It was based on modeling and very low-certainty evidence, and it assumes that test-directed indefinite treatment would actually be followed. Bleeding risk, patient preference, the strength and persistence of the trigger, and test validity remain relevant.
Why unprovoked does not automatically mean "order everything"#
An unprovoked clot has no major transient or persistent provoking factor identified. It carries a higher average recurrence risk than a surgery-provoked event. That might seem like the ideal setting for a hereditary panel, but ASH suggests not testing to guide duration after unprovoked venous thromboembolism.
The reason is decision logic. If recurrence risk already supports extended or indefinite anticoagulation for most suitable patients, a positive result does not change the plan, and a negative panel does not prove low recurrence risk and may encourage unsafe false reassurance. The relevant uncertainty is often bleeding risk and treatment preference, not whether one of a limited group of traits is present. Other guidelines and individual situations may frame the decision differently, particularly when stopping anticoagulation is being considered, and a hematology consultation can help you define whether any specific test has a plausible path to changing care.
Unusual-site thrombosis needs its own question#
Cerebral venous sinus thrombosis and splanchnic venous thrombosis do not fit ordinary leg-vein algorithms. ASH's recommendation depends on the local treatment strategy. If everyone would receive indefinite anticoagulation, testing adds little for duration, and if the standard plan is to stop after three to six months, testing may be considered when a positive result would lead to continuing treatment.
This illustrates why a guideline table cannot be reduced to one slogan. The same test can be low value in one pathway and decision-relevant in another. Cancer, inflammatory disease, and blood disorders may also need evaluation based on the site and presentation. So may liver disease, infection, pregnancy, and local anatomy.
Family history is about the specific defect#
Testing an asymptomatic relative merely because thrombosis "runs in the family" is often low yield. ASH distinguishes families with known high-risk deficiencies, such as antithrombin, protein C, or protein S deficiency, from families with lower-risk variants or an unspecified history.
Targeted testing for a known high-risk familial defect may help decide prevention during a temporary high-risk period or influence hormone or pregnancy planning. Broad panel testing in the general population before combined oral contraception is specifically discouraged; ASH's only strong recommendation in the 2023 guideline is against that practice.
Family counseling should begin by confirming what the affected relative actually had. "A clotting gene" in a message or problem list may be inaccurate. The original laboratory report, clot history, age, trigger, and degree of relationship all matter.
Why test timing can invalidate the answer#
Acute thrombosis changes hemostatic proteins, and anticoagulants interact with several assays. Warfarin lowers protein C and protein S, heparins can affect antithrombin and lupus-anticoagulant testing, and direct oral anticoagulants interfere with several clot-based assays. Pregnancy, estrogen, and liver disease can also change results. So can inflammation, nephrotic syndrome, and other conditions.
Genetic tests for factor V Leiden or the prothrombin variant are not altered by the acute clot or anticoagulation in the same way, but that does not make them automatically useful. Analytical validity and clinical utility are separate questions.
When a test is indicated, the laboratory and treating clinician need to plan the timing and interpret the result in light of current medicines and illness. Stopping anticoagulation solely to obtain a cleaner sample can create risk and should never be done without a supervised plan.
One abnormal result may not be a diagnosis#
Protein deficiencies often require confirmation after temporary causes and assay interference have been addressed. A low value during acute illness can normalize later. Reference ranges, method, and age all affect your interpretation. So do pregnancy status, liver function, and anticoagulant use.
Antiphospholipid syndrome requires both a qualifying clinical event and persistent laboratory findings under accepted criteria. Relevant antibodies must remain present on repeat testing at least 12 weeks apart. A transient low-level antibody during infection is not the same diagnosis.
Chart labels can outlive the uncertainty that created them. Once "thrombophilia" appears in a record, it can affect pregnancy counseling, contraception, and surgery. It can affect insurance questions, family anxiety, and willingness to stop anticoagulation. Confirming what is true is part of preventing harm.
What inappropriate testing can cost#
The direct cost of a panel is only one part. False or ambiguous positives lead to repeat tests and referrals. A mislabeled inherited deficiency can result in anticoagulation continued beyond its net benefit, adding bleeding risk. Negative results can falsely imply that recurrence risk has vanished.
An academic-center audit published in PLOS ONE found frequent testing without an appropriate indication, testing during the acute event, and incomplete confirmation of abnormal results. After ordering guidance was introduced, testing volume fell substantially. The study was observational and from one center, so it does not prove every downstream outcome, but it demonstrates how timing and indication errors cluster in real practice. Testing can also pull your attention away from more actionable factors: whether the event was truly provoked, cancer or inflammatory clues, adherence and interaction issues, bleeding risk, weight and mobility, future surgery, estrogen use, pregnancy plans, and symptoms of recurrence.
A decision-first consultation#
A careful discussion identifies the clot type and site, the strength and duration of provoking factors, prior events, age, family history, pregnancy and hormone context, cancer or inflammatory disease, and the anticipated anticoagulation plan. It then names the decision a result could change.
For each proposed assay, work through three outcomes. What happens if it is positive? What happens if it is negative? What happens if it is indeterminate or distorted? If all roads lead to the same plan, the test is unlikely to help you.
If a result could matter, timing, assay method, confirmation, and counseling should be planned before blood is drawn; this approach is more thorough than ordering every available test because it connects testing to patient-important consequences.
Safety boundaries#
Sudden shortness of breath, chest pain, or coughing blood can indicate pulmonary embolism and require emergency care. So can fainting, severe rapid heartbeat, or signs of shock. New one-sided leg swelling, pain, warmth, or discoloration needs prompt evaluation. Anticoagulant-associated major bleeding, black stools, or vomiting blood also needs urgent assessment. So does severe headache after injury, weakness, or uncontrolled bleeding.
Anticoagulation should not be stopped or extended based on this article or an isolated online result. Both clot recurrence and bleeding can be serious. Treatment duration and test interpretation require the clinician managing the event, with hematology input when the scenario is complex.
Sources and further reading
Questions and answers
Should everyone with an unprovoked clot receive a thrombophilia panel?
No. ASH suggests not testing solely to guide treatment duration when the recurrence risk already supports extended anticoagulation. A specific test may still be considered for a distinct decision after individualized review.
Is testing always inappropriate after a provoked clot?
No. ASH advises against testing after surgery-provoked events but conditionally suggests testing in selected nonsurgical transient-risk or hormone-associated scenarios when the result would change duration. The distinction and low certainty matter.
Can testing be done while taking an anticoagulant?
Some genetic assays are unaffected, while several protein and clot-based tests can be distorted. Never stop an anticoagulant to facilitate testing without a clinician-directed safety plan.
Does one positive antiphospholipid antibody test prove the syndrome?
No. Diagnosis requires a qualifying clinical event plus persistent laboratory findings confirmed at the required interval and interpreted in context.
Should relatives be tested after one family member has a clot?
Not automatically. Targeted testing may help when a known high-risk familial deficiency would change prevention or hormone or pregnancy decisions. A vague family history alone does not justify a broad panel.